Want to see IN:BROOKS full AI Analyst Report?

Brooks Laboratories Limited (BROOKS) Price & Analysis

2 Followers

BROOKS Stock Chart & Stats

₹63.38

-₹1.20(-1.88%)

At close: Jul 28 4:00 PM EDT

₹63.38

-₹1.20(-1.88%)

Day’s Range― - ―

52-Week Range₹36.50 - ₹138.10

Previous CloseN/A

Volume7.49K

Average Volume (3M)4.07K

Market Cap

₹1.63B

Enterprise Value₹1.11K

Total Cash (Recent Filing)₹66.73M

Total Debt (Recent Filing)₹0.00

Price to Earnings (P/E)12.2

Beta1.61

Next Earnings

Nov 06, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)4.49

Shares Outstanding29,457,249

10 Day Avg. Volume6,252

30 Day Avg. Volume4,071

Financial Highlights & Ratios

PEG Ratio-0.01

Price to Book (P/B)0.89

Price to Sales (P/S)1.27

P/FCF Ratio21.48

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Conservative LeverageVery low leverage gives Brooks Laboratories financial flexibility and reduces the burden of interest and refinancing obligations. A sizable and growing equity base also provides greater capacity to withstand operating volatility or support future business needs without relying heavily on additional debt.

Profitability TurnaroundThe return to strong profitability after losses through FY2025 indicates materially improved earnings power. If the recovery persists, positive margins and ROE can strengthen internal capital generation, improve resilience, and provide a more durable base for reinvestment over the coming quarters.

Cash Flow RecoveryPositive operating and free cash flow represent a meaningful improvement from the substantial outflows recorded in earlier years. This recovery suggests that the business is beginning to convert operations into liquidity, which can support financial stability and reduce dependence on external funding.

Bears Say

Revenue ContractionA steep decline in revenue weakens confidence that the profitability rebound reflects durable business expansion. Continued top-line pressure could reduce operating leverage, limit the scale of future earnings, and make the current margin improvement harder to sustain across the next several quarters.

Weak Earnings-to-cash ConversionOperating cash flow converting to less than half of reported net income indicates that accounting profitability is not yet translating reliably into liquidity. The sharp free-cash-flow decline versus FY2025 further weakens confidence in the durability and quality of the earnings recovery.

Volatile ProfitabilityThe extended history of losses and highly variable margins shows that Brooks Laboratories has not yet established a consistently predictable earnings model. Such volatility raises the risk that the FY2026 margin rebound may prove uneven, particularly while revenue is contracting materially.

Brooks Laboratories Limited News

Brooks Laboratories Announces Strategic Merger of Joint Venture

Brooks Laboratories Limited ( ($IN:BROOKS) ) has shared an announcement. Brooks Laboratories Limited has announced a merger by...

1y ago

BROOKS FAQ

What was Brooks Laboratories Limited’s price range in the past 12 months?

Brooks Laboratories Limited lowest stock price was ₹36.50 and its highest was ₹138.10 in the past 12 months.

What is Brooks Laboratories Limited’s market cap?

Brooks Laboratories Limited’s market cap is ₹1.63B.

When is Brooks Laboratories Limited’s upcoming earnings report date?

Brooks Laboratories Limited’s upcoming earnings report date is Nov 06, 2026 which is in 35 days.

How were Brooks Laboratories Limited’s earnings last quarter?

Brooks Laboratories Limited released its earnings results on Aug 13, 2026. The company reported -₹0.607 earnings per share for the quarter.

Is Brooks Laboratories Limited overvalued?

According to Wall Street analysts Brooks Laboratories Limited’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Brooks Laboratories Limited pay dividends?

Brooks Laboratories Limited does not currently pay dividends.

What is Brooks Laboratories Limited’s EPS estimate?

Brooks Laboratories Limited’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Brooks Laboratories Limited have?

Brooks Laboratories Limited has 29,457,249 shares outstanding.

What happened to Brooks Laboratories Limited’s price movement after its last earnings report?

Brooks Laboratories Limited reported an EPS of -₹0.607 in its last earnings report. Following the earnings report the stock price went up 5%.

Which hedge fund is a major shareholder of Brooks Laboratories Limited?

Currently, no hedge funds are holding shares in IN:BROOKS

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Brooks Laboratories Limited

Brooks Laboratories Limited is a pharmaceutical enterprise engaged in the contractual manufacturing and distribution of medicinal products. The company serves both the Indian domestic market and international clients. Its comprehensive product portfolio includes carbapenem medications, various tablets, dry syrups, both liquid and powdered injectable solutions, and specialized eye and ear drops. Brooks Laboratories Limited was established in 2002 and is headquartered in Mumbai, India.